Publications

Prodrugs Publications

  1. Zakharova VM, Serpi M, Krylov IS, Peterson LW, Breitenbach JM, Borysko KZ, Drach JC, Collins M, Hilfinger JM, Kashemirov BA, McKenna CE. Tyrosine-Based 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) Prodrugs: Synthesis, Stability, Antiviral Activity, and In Vivo Transport Studies. Journal Med. Chem. 2011 Aug;54(16):5680-93. PMID:21812420.
  2. Tsume Y, Hilfinger JM, Amidon GL. Potential of Amino Acid/Dipeptide Monoester Prodrugs of Floxuridine in Facilitating Enhanced Delivery of Active Drug to Interior Sites of Tumors: A Two-Tier Monolayer In Vitro Study. Pharm Res. 2011 June 14.[Epub ahead of print]. PMID:21671137.
  3. Peterson LW, Kim J-S, Kijek P, Mitchell S, Hilfinger J, Breitenbach J, Borysko K, Drach JC, Kashemirov BA, McKenna CE. Synthesis, Transport and Antiviral Activity of Ala-Ser and Val-Ser Prodrugs of Cidofovir. Bioorganic & Medicinal Chemistry Letters  2011 Jul 1;21(13):4045-9. PMID:21641218.
  4. Tehler U, Nelson CH, Peterson LW, Provoda CJ, Hilfinger JM, Lee KD, McKenna CE, Amidon GL. Puromycin-sensitive aminopeptidase: An antiviral prodrug activating enzyme. Antiviral Res. 2010 Mar;85(3):482-9  PMID:19969024.
  5. Shen W, Kim JS, Mitchell S, Kish PE, Kijek P, Hilfinger JM. 5’-O-D-valyl araA, a Potential Prodrug for Improving Oral Bioavailability of the Antiviral Agent Vidarabine. Nucleosides Nucleotides Nucleic Acids 2009, 28(1):43-55. PMID:19116869.
  6. Shen W, Kim JS, Kish PE, Zhang L, Mitchell S, Gentry BG, Breitenbach JM, Drach JC, Hilfinger JM. Design and Synthesis of Vidarabine Prodrugs as Antiviral Agents. Bioorg Med Chem Lett. 2009, Feb 1;19(3):792-6. PMID:19097789.
  7. Tsume Y, Hilfinger JM, Amidon GL.  Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine:  Increased Transporter Affinity and Metabolic Stability. Mol Pharm 2008 Sep-Oct; 5(5):717-27. PMID:18652477.
  8. Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, Amidon GL.  Enhanced Absorption and Growth Inhibition with Amino Acid Monoester Prodrugs of Floxuridine by Targeting hPEPT1 Transporters.  Molecules 2008, Jun 28;13(7):1441-54. PMID:18719516.
  9. Eriksson U, Peterson LW, Kashemirov BA, Hilfinger JM, Drach JC, Borysko KZ, Breitenbach JM, Kim JS, Mitchell S, Kijek P, McKenna CE. Serine Peptide Phosphoester Prodrugs of Cyclic Cidofovir: Synthesis, Transport and Antiviral Activity. Mol Pharm. 2008, Jul-Aug;5(4):598-609. PMID:18481868.
  10. Nieman M, Burke F, Warnock M, Zhou Y, Sweigart J, Chen A, Ricketts D, Lucchesi B, Chen Z, DiCera E, Hilfinger J, Kim JS, Mosberg H, Schmaier A.  Thrombostatin FM Compounds: Direct Thrombin Inhibitors–Mechanism of Action In Vitro and In Vivo. J Thrombosis Haemostasis,  2008 May;6(5):837-45. PMID:18315550.
  11. Mittal S., Tsume Y., Landowski CP., Lee KD., Hilfinger JM., Amidon GL. Proline prodrug of melphalan, prophalan-1, demonstrates high therapeutic index in a murine melanoma model. Eur J Pharm Biopharm 2007 Nov; 67(3) 752-8 [Epub 2007 Apr.4]. PMID:17560100.
  12. U. Eriksson, J.M. Hilfinger, J-S. Kim, S. Mitchell, P. Kijek, K.Z. Borysko, J.M. Breitenbach, J.C. Drach, B.A. Kashemirov, C.E. McKenna. Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir. Bioorg Med Chem Lett. 2007 Feb 1;17(3):583-6 [Epub 2006 Nov 10]. PMID:17161946.
  13. Kim, J.S., S. Mitchell, P. Kijek, Y. Tsume, J.M. Hilfinger, and G.L. Amidon. The Suitability of an In Situ Perfusion Model for Permeability Determinations: Utility for BCS Class 1 Biowaiver Requests. Mol Pharm, 2006;3(6)686-94. PMID:17140256.
  14. Kish PE, Tsume Y, Kijek P, Lanigan TM, Hilfinger JM, Roessler BJ. Bile Acid – Oligopeptide Conjugates Interact with DNA and Facilitate Transfection. Mole Pharm 2007 Jan-Feb;4(1):95-103. PMID:17274667.
  15. McKenna CE, Kashemirov BA, Eriksson U, Amidon GL, Kish PE, Mitchell S, Kim JS and Hilfinger JM.  Cidofovir peptide conjugates as prodrugs.  J. Organomet. Chem (2005) 690; 2673-2678.
  16. Song, X., P.L. Lorenzi, C.P. Landowski, B.S. Vig, J.M. Hilfinger, and G.L. Amidon, Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm, 2005. 2(2): p. 157-67. PMID:15804190.
  17. Lorenzi, P.L., C.P. Landowski, X. Song, K.Z. Borysko, J.M. Breitenbach, J.S. Kim, J.M. Hilfinger, L.B. Townsend, J.C. Drach, and G.L. Amidon. Amino Acid Ester Prodrugs of 2-Bromo-5,6-dichloro-1-({beta}-D-ribofuranosyl)benzimidazole Enhance Metabolic Stability in Vitro and in Vivo. J Pharmacol Exp Ther, 2005. 314(2): p. 883-90. PMID:15901797.
  18. S. Mittal, X. Song, B.S. Vig, C.P. Landowski, I. Kim, J.M. Hilfinger, and G.L. Amidon, Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs. Mol Pharm, 2005. 2(1): p. 37-46. PMID:15804176.
  19. C.P. Landowski, X. Song, P.L. Lorenzi, J.M. Hilfinger, and G. L. Amidon, Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res, 2005. 22(9): p. 1510-8. PMID:16132363.
  20. Delaney B, Stevens LA, Schmelzer W, Haworth J, McCurry S, Hilfinger JM, Kim JS, Tsume Y, Amidon GL, Kritchevsky D., Oral absorption of phytosterols and emulsified phytosterols by Sprague-Dawley rats.  J Nutr Biochem. 2004 May;15(5):289-95. PMID:15135053.
  21. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL.  Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis.Pharm Res. (2003) Sep;20(9):1381-8. PMID:1457631.
  22. Zimmermann EM, Schmiedlin-Ren L, Chamberlain J, Sabek M, Hilfinger JM, Parks E, Roessler BJ.  Serotype 5 recombinant adenovirus selectively tranduces epithelial cells with a de-differentiated phenotype. American Gastroenterological Association, (2001).
  23. Hsu C, Walter E, Merkle H, Rothen-Rutishauser B, Wunderli-Allenspach H, Hilfinger J, Amidon G.  Function and immunolocalization of overexpressed human intestinal h+/peptide co-transporter in adenovirus-transduced caco-2 cells. AAPS PharmSci (1999);1 (3):E12. PMID:11741208.
  24. Hsu CP, Hilfinger JM, Walter E, Merkle HP, Roessler BJ, Amidon GL., Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharmaceutical Research, 15(9):1376-81, (1998).  PMID:9755888.
  25. C.P. Hsu, J.M. Hilfinger and G.L. Amidon, Overexpression of human intestinal oligopeptide transporter in rat and human intestinal epithelial cell lines via adenoviral, Pharm.Res., 14, S-23 (Nov 1997) Boston, MA.
  26. Ezra, A., Hoffman, A., Breuer, E., Weiss, G., Lipka, E., Amidon, G.L., Golomb, G.: Peptidyl prodrugs for improved oral absorption. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 24, p. 243 (1997)
  27. Ezra, A., Breuer, E., Amidon, G.L., Hoffman, A., Ornoy, A., Patlas, N., Weiss, G., Lipka, E., Crison, J., Golomb, G.: Peptidyl prodrug of bisphosphonates for improved oral absorption. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 23, p. 83 (1996)
  28. Ezra, A., Breuer, E., Amidon, G.L., Hoffman, A., Lipka, E., Weiss, G., Crison, J., Golomb, G.: Novel Bisphosphonates and Pepdidyl Prodrugs for Improved Oral Absorption. Pharm.Res. 13(9): S-358 (1996).
  29. Lipka E, Crison JR, Amidon GL: Transmembrane Transport of Peptide Type Compounds: Prospect for Oral Delivery. J. Control. Rel. 39:121-129, (1996). PMID:11539926.

return to top

Formulation Publications

  1. Tubic-Grozdanis M, Hilfinger JM, Amidon GL, Kim JS, Staubach P, Langguth P.  Pharmacokinetics of CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms.  Pharm Res 2008 Jul;25(7):1591-600. PMID:18213452.
  2. Kish PE., Kim J-S., Roessler B., Campbell S., Hilfinger JM. Bile acid conjugates improve the oral bioavailability of the neuraminidase inhibitor zanamivir. Presented at the 20th ICAR meeting, Rancho Mirage, California, April 30, (2007).
  3. M.P. Desai, J.M. Hilfinger, G.L. Amidon, R.J. Levy and V. Labhasetwar, Immune response with biodegradable nanospheres and alum: studies in rabbits using staphylococcal enterotoxin B-toxoid, J.Microencapsulation, 17, 215 (2000). PMID:10738697.
  4. Y. Tsume, J.M. Hilfinger, C.A. Siersma, J. Kim and G.L. Amidon, An oral controlled release system for small animals: in vivo testing of the PORT System capsule, 2000 AAPS Annual Meeting, Oct 29-Nov 2, (2000), Indianapolis, IN
  5. Kim JS, Amidon GL.  Oral Delivery of Dietary Supplements:  Pharmaceutical and Mechanistic Approach. AAPS Dietary Supplements Forum.  June 28-30, (2000).
  6. R. Loebenberg, JS Kim, J. Crison and G.L. Amidon, Controlled release of metoprolol: influence of motility and food, Controlled Release Society Meeting, July (2000), Paris, France.
  7. Crison JR, Vieira ML, Kim JS, Siersma C, Amidon GL. Pulsatile, Multiple Dose, Delivery System for Therapeutic Optimization. Controlled Release Society Annual Meeting, Paris, France (2000).
  8. Loebenberg R, Kim JS, Crison JR, Amidon GL, Effect Of Food On The Pulsatile Delivery Of Metoprolol. Pharm. Res. 15: (1999).
  9. Axelrod HR, Kim JS, Longley CB, Lipka E, Amidon, GL, Kakarla R, Hui YW, Weber S, Choe S, Sofia MJ. Intestinal transport of gentamicin with a transphore: A novel, facially amphiphilic, glycosteroid drug transport agent. Pharm. Res 15(12):1876-1881, (1998). PMID:9892472.
  10. Crison JR, Lipka E, Kim JS, Amidon GL: Lipid-filled hard gelatin capsules as novel drug delivery systems with application to nifedipine. Bulletin Technique Gattefosse, Gattefosse, (1997).
  11. J.M. Hilfinger, E.M. Zimmermann, B.J. Roessler and G.L. Amidon, Oral adenovirus for treatment of inflammatory bowel disease, Proc.Intl.Symp. CRS, 24, 681 (1997).
  12. Crison JR, Siersma PR, Amidon GL.  A Novel Programmable Oral Release Technology for Delivering Drugs:  Human Feasibility Testing Using Gamma Scintigraphy.  Proceed. Int’l Symp. Control. Rel. Bioact. Mater. 23;2 (1996)
  13. Crison JR, Siersma PR, Lipka E, Taylor MD, Amidon GL: Programmable Oral Release Technology, PORT System A Novel Dosage Form for Time and Site Specific Oral Drug Delivery. Proceed. Int’l.. Symp. Control. Rel. Bioact. Mater. 22, p.278 (1995)
  14. Bleske BE, Welage LS, Rose S, Amidon GL, Shea MJ. The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. J. Clin. Pharmacol., 35,374 (1995)
  15. Axelrod, H., Walker, S., Venkatesan, P., Kim, J.S., Sofia, M., Kakarla, R., Chan, T.Y., Amidon, G., Lipka, E., Choe, S., Babu, D., Kahne, S.: Oral Bioavailability of Gentamicin is Increased by Using a Transphore. Pharm. Res. 12(9): S-311 (1995).

return to top

Permeability, Drug Transport & BCS Publications

  1. Okawada M, Koga H, Larsen SD, Showalter HD, Turbiak AJ, Jin X, Lucas PC, Lipka E, Hilfinger JM, Kim JS, Teitelbaum DH. Use of Enterally Delivered Angiotensin II Type 1a Receptor Antagonists to Reduce the Severity of Colitis. Dig Dis Sci. 2011 Mar 12 [Epub ahead of print] PMID:21399927.
  2. Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernäs H, Amidon GL. High-Permeability Criterion for BCS Classification:  Segmental/pH Dependent Permeability Considerations. Mol Pharm. 2010 Sep 3. [Epub ahead of print] PMID: 20701326.
  3. Hilfinger JM. BCS in Drug Discovery, Development and Regulation. Mol Pharm 2009, Jan-Feb;6(1):1. PMID:19183103.
  4. Delaney B, Stevens LA, Schmelzer W, Haworth J, McCurry S, Hilfinger JM, Kim JS, Tsume Y, Amidon GL, Kritchevsky D., Oral absorption of phytosterols and emulsified phytosterols by Sprague-Dawley rats.  J Nutr Biochem. 2004 May;15(5):289-95. PMID:15135053.
  5. Kim, J.S., S. Mitchell, P. Kijek, Y. Tsume, J.M. Hilfinger, and G.L. Amidon, The Suitability of an In Situ Perfusion Model for Permeability Determinations: Utility for BCS Class 1 Biowaiver Requests. Mol Pharm, (2006);3(6)686-94. PMID:17140256.
  6. International Bioequivalence Standards: A NEW ERA, (editors) Amidon GL, Lesko L, Midha K, Shah V, Hilfinger JM, TSRL, Inc. Ann Arbor, (2006).
  7. Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernas H, Hussain A, Lesko L, Amidon GL.  Human jejunal permeability of two polar drugs:  cimetidine and ranitidine.  Pharm. Res. Jun;18(6):742-4. (2001)
  8. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P.  Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.  J. Pharm. Sci. Jan;89(1):63-75. (2000).
  9. Lipka E and Amidon GL: Setting bioequivalence requirements for drug development based on preclinical data: Optimizing oral drug delivery systems. J. Control. Rel. 62(1-2), p. 41-50, (1999) PMID:10518633.
  10. Li L, Kim JS, Heimbach T, Fleisher D. Region-Dependent Metabolism and Permeability of Indinavir in Rat Intestine. Pharm. Res. 15: (1999).
  11. Siersma CA, Kim JS, Clark L, Walton J, and Amidon GL. Evaluation of a Rank Order of the Permeability Ratios of Various Compounds for Categorization into the Biopharmaceutics Classification System. Pharm. Res. 15: (1999).
  12. J.R. Crison, E. Lipka, G.L. Amidon: Effect of release rate and permeability on fraction dose absorbed of a highly soluble drug in the ascending colon. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 25, (1998)
  13. Amidon GL. Biopharmaceutics classification system: Interview with Prof. Gordon Amidon, Dissoln. Tech., Nov. (1998).
  14. Lipka E, Spahn-Langguth H, Mutschler E, Amidon GL.  In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs:  evidence for intestinal secretion.  Eur. J. Pharm. Sci.  Jan;6(1):75-81 (1998).
  15. Langguth P, Amidon GL, Lipka E, Spahn-Langguth H, Gastrointestinal Transport Processes: Potentials for Stereoselectivities at Substrate-Specific and Nonspecific Epithelial Transport Systems.  In: “The Impact of Stereochemistry on Drug Development and Use”, ed. Aboul-Enein HY and Wainer, IW, John Wiley & Sons, Inc. (1997)
  16. Lipka E, Hilfinger JM, Siersma CA, Crison JR, Ridgewell RE, Amidon GL: Evaluation of imiquimod and analogues with respect to their oral delivery potential. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 24, p.337 (1997)
  17. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL  HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. Journal of Pharmaceutical Science, 85(10):1070-6, (1996). PMID:8897273.
  18. Yu LX, Lipka E, Crison JR,  Amidon GL: Transport Approaches to the Biopharmaceutical Design of Oral Drug Delivery Systems: Prediction of Intestinal Absorption. Advan. Drug Deliv. Rev. 19:359-376, (1996) PMID:11540095.
  19. E. Lipka, J.S. Kim, J.R. Crison, S. Roy, G.L. Amidon, “Oral Absorption of the HIV-Protease Inhibitor AG1343: A Function of Site Specific Permeability and pH Dependent Solubility”, AAPS National Meeting, (1996).
  20. Gibbons, J.A., Lipka, E., Siersma, C.A., Crison, J.R., Breakman, R.A., Amidon GL: Absorption of Drugs into Prehepatic Blood: Correlation between In Situ Absorption and Effective Permeability in Humans. Pharm.Res. 13(9): S-416 (1996).
  21. Lipka E, Yu L, Liu D, Crison JR, Amidon GL: Evaluation of the Intestinal Permeabilities of b-Blocker Drugs and Their Potential for Oral Controlled Release. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22, p.366 (1995)
  22. Amidon GL, Lennernas H, Shah V, Drison J.  A Theoretical Basis for a Biopharmaceutic Drug Classification:  The Correlation of In Vitro Drug Product Dissolution and In Vivo bioavailability (1995) Pharm. Res. 12 (3) 413-20. PMID:7617530.
  23. Lennernas H, Crison J, Amidon GL.  Permeability and Clearance Views of Drug Absorption:  A Commentary. (1995) J. Pharmacokinet. Biopharm. 23 (3) 333-43. PMID:8834200.

return to top

Solubility & Dissolution Publications

  1.  Jinno J. Oh D, Crison J, Amidon GL. Dissolution of Ionizable Water-Insoluble Drugs: The Combined Effect of pH and Surfactant. (2000) J. Pharm. Sci. 89 (2) 268-74. PMID:10688756.
  2. Crison JR, Fleisher D. Preface: Advanced Drug Delivery Rev. 42(3): 163-4 (2000) PMID:10963833.
  3. Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, Denny WA.  Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-)phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubulizing functions.  J. Med. Chem. Apr6;43(7):1380-97. (2000)
  4. Loebenberg R, Vieira M, Amidon GL. Solubility as a limiting factor to drug absorption, In: Methods for Assessing Oral Drug Absorption, J.B> Dressman (Ed), Marcel Dekker, NY sub. Sept (1998)
  5. Crison JR, Amidon GL. Predicting absorption of water insoluble compounds and other “difficult” molecules, Bull. Tech. Gattefosse, 90,21 (1997)
  6. Crison JR, Weiner ND, Amidon GL. Dissolution Media for In Vitro Testing of Water-Insoluble Drugs:  Effect of Surfactant purity and Electrolyte on In Vitro Dissolution of Carbamazepine in Aqueous Solutions of Sodium Lauryl Sulfate. (1997) J. Pharm. Sci. 86(3) 384-8. PMID:9050810.
  7. Amidon GL, Choe SY, Vieira M, Oh DM. Solubility, intrinsic dissolution and solubilization: Influence on absorption, Scientific Foundations for Regulating drug Product Quality, Amidon GL, Robinson JR, Williams RL (Eds), AAPS Press, Alexandria, VA pp. 99-113 (1997)
  8. Crison J, Shah V, Skelly J, Amidon GL.  Drug Dissolution into Micellar Solutions:  Development of a Convective Diffusion Model and Comparison to the Film Equilibrium Model with Application to Surfactant-Facilitated Dissolution of Carbamazepine. (1996) 85 (9) 1005-11. PMID:8877894.
  9. Crison JR, Amidon GL. Expected variation in bioavailability for water insoluble drugs, in Bio-International 2, H.H. Blume and K.K. Midha (Eds) Medpharm Scientific Pub., (Stuttgart, Germany) pg. 301; (1995)

return to top

Gene Delivery Publications

  1.  Kish PE, Tsume Y, Kijek P, Lanigan TM, Hilfinger JM, Roessler BJ. Bile Acid – Oligopeptide Conjugates Interact with DNA and Facilitate Transfection. Mole Pharm (2007) Jan-Feb;4(1):95-103. PMID:17274667.
  2. Parks E, Hilfinger JM, Zimmermann EM, Roessler BJ. Gene transfer via oral composite nano/microparticles to murine intestinal tissue. Gastroenterology, 118:A3044, (2000).
  3. Chamberlain JR, Shaw MH, Hilfinger JM, Zimmermann EM, Roessler BJ. Recombinant adenovirus serotype switching for analysis of efficiency and route of intestinal cell entry. Gastroenterology, 118:A671, (2000).
  4. Matthews C, Jenkins G, Hilfinger JM, and Davidson B.  Poly-L-lysine improves gene transfer with adenovirus formulated in PLGA microspheres. Gene Ther. (1999) Sep; 6(9): 1558-64. PMID:10490765.
  5. Croyle MA, Roessler BJ, Davidson BL, Hilfinger JM, Amidon GL. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharmaceutical Development Technology, 3(3):373-83, (1998). PMID:9742558.
  6. Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, Davidson BL. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Therapy, 5(6):740-6, (1998) PMID:9747453.
  7. E. Walter, M.A. Croyle, B.L.Davidson, B.J. Roessler, J.M. Hilfinger and G.L. Amidon, Adenovirus mediated gene transfer to intestinal epithelial cells as a potential approach for oral delivery of peptides and proteins, J.Cont. Rel. 46(1): 75-87. (1997).
  8. Walter E, Croyle MA, Davidson B, Roessler BJ, Hilfinger JM, Amidon GL. Caco-2 cells as an in vitro model for adenoviral gene transfer to the gut epithelium. (1997), J. Controlled Release 46:57-68.

return to top

Pharmacokinetics & IVIVC Publications

  1.  Loebenberg R, Kim JS, Amidon GL.  Pharmacokinetics of an Immediate Release, a Controlled Release and a Two Pulse Dosage Form in Dogs. (2005) Eur. Journal Pharm. Biopharm. 60 (1) 17-23.
  2. Delaney B, Stevens LA, Schmelzer W, Haworth J, McCurry S, Hilfinger JM, Kim JS, Tsume Y, Amidon GL, Kritchevsky D., Oral absorption of phytosterols and emulsified phytosterols by Sprague-Dawley rats. J Nutr Biochem. (2004) May;15(5):289-95. PMID:15135053.
  3. Gilman TM, Rose JP, Lipka E, Amidon GL, Woltosz WS, Crison J, Bolger MB: GastroPLUSÔ simulated intestinal absorption of drug delivery systems for metoprolol. In: Proceedings of the 1999 Health Sciences Simulation Conference, Anderson JG, Katzper M, Eds., The Society for Computer Simulation International, San Diego, USA pp. 109-114, (1999).
  4. Kaus LC, Gillespie WR, Hussain AS, Amidon GL. The effect of in vivo dissolution, gastric emptying rate and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm. Res. ,16, 272 (1999)
  5. Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans, Int’l. J. Pharm., 171 157 (1998)
  6. Siersma CA, Kim JS, Lipka E, Chattaraj S, Crison J, Amidon GL.  In Vitro-In Vivo Correlation of a Pulsatile Release Delivery System for Pseudoephedrine in the Dog. Pharm. Sci. 1(1): S-495. (1998).
  7. Polli J, Crison J, Amidon GL. Novel Approach to the Analysis of In Vitro-In Vivo Relationships. (1996) J. Pharm. Sci. 85 (7) 753-60. PMID:8819002.
  8. Lipka, E., Kim, J.S., Siersma, C.A., Crison, J.R, Amidon G.L: Drug Delivery Utilizing a Novel Programmable Oral Release Technology: In Vivo – In Vitro Correlation of Release Times. 23rd  Proceed. Intern. Symp. Control. Rel. Bioact. Mater, Kyoto, Japan. p. 575 (1996)
  9. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int’l. J. Pharm., 140,111 (1996)
  10. Lipka E, Crison JR, Schug BS, Blume HH, Amidon GL: Drug Interactions in the gastrointestinal tract and their impact on drugl absorption and systemic availability: A Mechanistic Review. In: “Mechanisms of Drug Interactions”, ed. D’Arcy, P.F., McElnay, J.C., Welling, PG (Eds) Springer Verlag, Berlin Heidelberg, Ch 2,13 (1996).
  11. Choe, S., Lipka, E., Yu, L., Crison, J.R., Amidon GL: Optimization of Dosage Form Release Parameters Based on Pharmacokinetic and Gastrointestinal Transit Time Considerations. Pharm.Res. 13(9): S-292 (1996).
  12. Lipka E, Lee KD, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL. Celiprolol double peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs. J. Pharm. Biopharm>, 23, 267 (1995) PMID:8834196.

return to top

  • Contract Services
  • Technology & Licensing
  • Resources
    • © 2012 TSRL, INC. ORAL DRUG DELIVERY TECHNOLOGIES.